SI3240538T1 - Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo - Google Patents

Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo

Info

Publication number
SI3240538T1
SI3240538T1 SI201730997T SI201730997T SI3240538T1 SI 3240538 T1 SI3240538 T1 SI 3240538T1 SI 201730997 T SI201730997 T SI 201730997T SI 201730997 T SI201730997 T SI 201730997T SI 3240538 T1 SI3240538 T1 SI 3240538T1
Authority
SI
Slovenia
Prior art keywords
masitinib
treatment
lateral sclerosis
amyotrophic lateral
patient subpopulation
Prior art date
Application number
SI201730997T
Other languages
English (en)
Inventor
Alain Moussy
Jean-Pierre Kinet
Colin Mansfield
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of SI3240538T1 publication Critical patent/SI3240538T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SI201730997T 2016-03-25 2017-03-24 Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo SI3240538T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP17712175.3A EP3240538B1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (1)

Publication Number Publication Date
SI3240538T1 true SI3240538T1 (sl) 2022-02-28

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730997T SI3240538T1 (sl) 2016-03-25 2017-03-24 Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo

Country Status (20)

Country Link
US (1) US10092564B2 (sl)
EP (1) EP3240538B1 (sl)
JP (2) JP7250312B2 (sl)
KR (1) KR102293847B1 (sl)
CN (1) CN108883108B (sl)
AU (1) AU2017236177B2 (sl)
BR (1) BR112018069515A2 (sl)
CA (1) CA3018635C (sl)
DK (1) DK3240538T3 (sl)
EA (1) EA038531B1 (sl)
ES (1) ES2899929T3 (sl)
HU (1) HUE057398T2 (sl)
IL (1) IL261856B (sl)
MX (1) MX2018011349A (sl)
NZ (1) NZ745778A (sl)
PL (1) PL3240538T3 (sl)
PT (1) PT3240538T (sl)
SG (1) SG11201808106YA (sl)
SI (1) SI3240538T1 (sl)
WO (1) WO2017162884A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
CN109922800B (zh) * 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
DK3425390T3 (da) 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
US20200093801A1 (en) * 2017-03-28 2020-03-26 Novartis Ag New methods for the treatment of multiple sclerosis
CN111328283A (zh) * 2017-05-30 2020-06-23 德西费拉制药有限责任公司 1-[4-溴-5-[1-乙基-7-(甲氨基)-2-氧代-1，2-二氢-1，6-萘啶-3-基]-2-氟苯基]-3-苯基脲和类似物用于治疗与血小板衍生的生长因子受体α中的遗传异常相关的癌症的用途
WO2019173361A2 (en) 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (sl) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
BRPI0313165B8 (pt) 2002-08-02 2021-05-25 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ES2522169T3 (es) 2007-02-13 2014-11-13 Ab Science Forma polimorfa de derivado de 2-amino (nitroaril) tiazol
AR080933A1 (es) 2010-04-20 2012-05-16 Ab Science Tratamiento de esclerosis multiple con masitinib
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
AU2013326463B2 (en) * 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EP3388436B1 (en) * 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
CA3018635C (en) 2023-09-26
AU2017236177A1 (en) 2018-09-20
ES2899929T3 (es) 2022-03-15
MX2018011349A (es) 2019-02-07
US10092564B2 (en) 2018-10-09
CA3018635A1 (en) 2017-09-28
IL261856A (en) 2018-10-31
NZ745778A (en) 2022-07-01
BR112018069515A2 (pt) 2019-04-16
DK3240538T3 (da) 2021-12-06
JP2019515884A (ja) 2019-06-13
PL3240538T3 (pl) 2022-01-31
JP2022037132A (ja) 2022-03-08
WO2017162884A1 (en) 2017-09-28
HUE057398T2 (hu) 2022-05-28
IL261856B (en) 2022-04-01
KR20180125966A (ko) 2018-11-26
SG11201808106YA (en) 2018-10-30
PT3240538T (pt) 2021-12-07
KR102293847B1 (ko) 2021-08-26
CN108883108A (zh) 2018-11-23
US20180117037A1 (en) 2018-05-03
EP3240538B1 (en) 2021-09-29
EA201800499A1 (ru) 2019-03-29
EP3240538A1 (en) 2017-11-08
AU2017236177B2 (en) 2022-03-31
EA038531B1 (ru) 2021-09-10
CN108883108B (zh) 2021-08-06
JP7250312B2 (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
IL261856B (en) Use of masitinib to treat a subpopulation of amyotrophic lateral sclerosis patients
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
IL253945A0 (en) kdm1a inhibitors to treat the disease
IL272444A (en) Compounds, their salts and methods for treating diseases
IL275482A (en) Asketamine for the treatment of depression
IL268694A (en) Treatment of schizophrenia
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
IL254266A0 (en) Glucosylceramide synthase inhibitors for the treatment of diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
HK1258994A1 (zh) 用於疾病治療的方法
HK1252207A1 (zh) 一種組合物在製備治療肌萎縮性側索硬化症藥物中的應用
ZA201902385B (en) Compounds and methods for diagnosis and treatment of viral infections
PT3286317T (pt) Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
IL261116A (en) A drug for the treatment of diabetic foot infections
IL268187A (en) Use of Snickepok to treat stroke
EP3310310A4 (en) DEVICE FOR TREATING MENIÈRE DISEASE
IL269681A (en) New methods for treating multiple sclerosis
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
IL259381B (en) Miravegron for the treatment of retinal diseases
EP3448869A4 (en) AZASTEROIDS FOR TUBERCULOSIS TREATMENT
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
AU2015901877A0 (en) Treatment of amyotrophic lateral sclerosis